TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06038175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care neurologic evaluation
Description: A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care neurologic evaluation
Description: A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
Study: NCT06650852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection
Study: NCT02124187

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine free inhalator
Description: eCig 24 mg nicotine for 12 weeks
Study: NCT03223220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam injection
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: Injection
Study: NCT06516796

Intervention type: OTHER
Intervention: No intervention
Description: Patients were retrospectively screened.
Study: NCT06650852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of BRII-179
Description: Placebo of BRII-179 will be given via intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of BRII-835
Description: Placebo of BRII-835 will be given via subcutaneous injection
Study: NCT06650787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound was used to locate the end of the gastric tube
Description: 1. Inform the family of the purpose and method of using bedside ultrasound to guide the placement of the gastric tube, and determine the position of the end of the tube.~2. The ultrasound machine was connected to the power supply and placed on the right side of the patient.~3. Select the appropriate type of gastric tube and measure the length of the indwelling gastric tube by nursing staff before inserting the tube.~4. Nurses who had been trained in ultrasound performed ultrasound judgment on the neck and abdomen of the children. Sonographers, intensive care physicians and nursing staff jointly judged the ultrasound images.~5. Conventional judgment method was used to determine the position of gastric tube~6. Bedside chest radiography, with results obtained by a radiologist.~7. Keep your child safe at all times.
Study: NCT06516796

Intervention type: OTHER
Intervention: No intervention
Description: Patients were retrospectively screened.

Intervention type: OTHER
Intervention: No intervention
Description: Patients were retrospectively screened.
Study: NCT06650787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional placing nasogastric tube group
Description: 1. Choose the appropriate type of gastric tube, and measure the length of the indwelling gastric tube by the nursing staff before the tube insertion.~2. The gastric tube was inserted by the conventional blind insertion method.~3. The conventional judgment method was used to determine the position of the gastric tube.~4. Bedside chest radiography, with results obtained by a radiologist.~5. Keep your child safe at all times.
Study: NCT06040476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCB
Description: hUCB
Study: NCT04371172

Intervention type: OTHER
Intervention: cognitive research battery, MRI, laboratory values
Description: cognitive research battery, MRI, laboratory values
Study: NCT05292404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: conventional treatment were given according to international uniformguidelines
Study: NCT06329141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutiglabridin
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutiglabridin
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study: NCT04681508

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest CT without contrast enhancement and chest X-ray
Description: Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
Study: NCT05405049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Description: Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
Study: NCT06531915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
Study: NCT06679712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial PDT lung tumor ablation
Description: Transbronchial photodynamic therapy ablation for peripheral lung cancer
Study: NCT06678061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: block of neurolytic retrocrural celiac plexus block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: block of neurolytic retrocrural celiac plexus block
Study: NCT05106894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone application to promote nurturing care
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: printed caregiving materials
Description: see arm description
Study: NCT06081855

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Measuring aortic root diameter by CT

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Measuring aortic root diameter by CT
Study: NCT05052411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App usage assessments and analytics
Description: All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
Study: NCT05008341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg Oral Tablet
Description: Single-dose 150 mg tablet orally administered.
Study: NCT05991505

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Multimodal exercises twice a week
Study: NCT05193422

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry - baseline
Description: Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry - post CPET
Description: Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry - post CPET
Description: Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal peak inspiratory flow - baseline
Description: Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal peak inspiratory flow - baseline
Description: Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal peak inspiratory flow - post CPET
Description: Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal peak inspiratory flow - post CPET
Description: Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation
Description: Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Description: Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate
Description: Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
Study: NCT05557890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System Constellation VR-Seminar
Description: individual-centered intervention in a group VR-setting, duration 2 to 3 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System Constellation VR-Seminar
Description: individual-centered intervention in a group VR-setting, duration 2 to 3 days
Study: NCT05193422

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart Rate
Description: Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: End-tidal CO2
Description: Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-tidal CO2
Description: Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory rate
Description: Continuous monitoring of RR using a Microstream capnograph, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory rate
Description: Continuous monitoring of RR using a Microstream capnograph, in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Temperature
Description: Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Humidity
Description: Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise testing
Description: CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing
Description: CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Discomfort level
Description: Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Discomfort level
Description: Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET.
Study: NCT04950894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglossal Nerve Stimulation
Description: Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)

Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglossal Nerve Stimulation
Description: Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
Study: NCT06153446

Intervention type: DIAGNOSTIC_TEST
Intervention: Synovasure® Comprehensive Infection Panel
Description: The Synovasure Comprehensive PJI Test Panel (PJI Panel) is a laboratory-developed test (LDT) panel (CD Laboratories, CLIA Registration No.: 21D0216863) intended to aid the diagnosis of PJI.
Study: NCT05237232

Intervention type: OTHER
Intervention: Magnetic Resonance Angiography (MRA) additional acquisition time
Description: Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.

Intervention type: OTHER
Intervention: Modeling cerebral vascularization
Description: The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling \& Simulation) requires several inputs:~* The MRA images~* The cardiac function curve~* The cerebral blood flow~* Measurement of systolic, diastolic and mean arterial blood pressure

Intervention type: OTHER
Intervention: Modeling cerebral vascularization
Description: The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling \& Simulation) requires several inputs:~* The MRA images~* The cardiac function curve~* The cerebral blood flow~* Measurement of systolic, diastolic and mean arterial blood pressure
Study: NCT06574178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: A Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
Study: NCT05099393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non Nutritive Sweeteners
Description: The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non Nutritive Sweeteners
Description: The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period.
Study: NCT06331949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video assisted training
Description: Ebelik bakımının yanı sıra NST konusunda eğitim içerikleri, eğitim videoları ve broşür destekli eğitimler verilecek. NST cihazı takılacak ve standart olarak işlem başladıktan 5 dakika sonra NST kaydı sırasında cihazdan gelen fetal kalp sesinin şiddeti artırılarak fetal kalp sesinin devam etmesi sağlanacaktır. Transfer edilecek hamile kadın yaklaşık 2 dakika kadar dinlenecektir.
Study: NCT06042608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intercostobrachial nerve block
Description: injection of local anesthetic to target the intercostobrachial nerve in the axilla

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intercostobrachial nerve block
Description: injection of local anesthetic to target the intercostobrachial nerve in the axilla
Study: NCT06638970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome
Description: 3 ml Injection of secretome for 4 times two weeks apart
Study: NCT06642181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine pharmacotherapy
Description: It is a pharmacotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine pharmacotherapy
Description: It is a pharmacotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement (MORE)
Description: It is a mindfulness intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement (MORE)
Description: It is a mindfulness intervention
Study: NCT06253767

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endodontic Treatment
Description: Conventional endodontic treatment will be performed equally on all participants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Treatment
Description: Conventional endodontic treatment will be performed equally on all participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Treatment Group (TG) will receive photobiomodulation for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Simulation Low Level Laser therapy
Description: A simulation of low-level laser therapy was performed on the control group starting from patient preparation (placement of glasses) and the reproduction of device sounds without activation.
Study: NCT06467760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InDx CMC Implant
Description: The InDx CMC Implant is a hemiarthroplasty device for the CMC joint which consists of a unified assembly of three components: metacarpal stem, polyethylene liner, and articulating head. Because the device functions as a hemiarthroplasty, it does not link or constrain the CMC joint
Study: NCT06059378

Intervention type: DEVICE
Group type: OTHER
Intervention: Artificial intelligence-assisted classification (CADx)
Description: CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
Study: NCT05061966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immi
Description: The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
Study: NCT05335057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
Study: NCT06316258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy group
Description: 6 session compassion focused therapy group for adults with ABI